Viewing Study NCT04220203


Ignite Creation Date: 2025-12-24 @ 7:21 PM
Ignite Modification Date: 2026-02-24 @ 8:26 AM
Study NCT ID: NCT04220203
Status: APPROVED_FOR_MARKETING
Last Update Posted: 2025-06-26
First Post: 2020-01-03
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Eligibility Module